Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 5/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130970 | 0.84 | GRM5 (0.45) | ALDH1A1LMNATSHRHTTGRM5 | |
| SCHEMBL5130079 | 0.82 | ALDH1A1 (0.59) | ALDH1A1LMNATSHRSMN1; SMN2MAPT | |
| SCHEMBL5121839 | 0.81 | MGLL (0.46) | ALDH1A1LMNATSHRHTTMEN1 | |
| SCHEMBL5129768 | 0.80 | GRM5 (0.54) | ALDH1A1L3MBTL1GRM5 | |
| SCHEMBL5122913 | 0.80 | ALDH1A1 (0.59) | ALDH1A1TSHRHTTSMN1; SMN2MEN1 | |
| SCHEMBL5123112 | 0.80 | CRBN (0.53) | LMNAHTTSMN1; SMN2GRM5CYP3A4 | |
| SCHEMBL5115906 | 0.80 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5118654 | 0.79 | KMT2A (0.51) | ALDH1A1TSHRSMN1; SMN2KMT2AGRM5 | |
| SCHEMBL5119789 | 0.79 | MEN1 (0.48) | ALDH1A1LMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL5123091 | 0.79 | GRM5 (0.43) | ALDH1A1LMNATSHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1856107-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | Novartis AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089700-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | NOVARTIS AG (CH) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | ALDH1A1 908/4885LMNA 4443/4885TSHR 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.